Login to Your Account



Clinic Roundup


Monday, June 17, 2013
Updated results of a Phase I/II study of daratumumab in heavily pretreated patients with multiple myeloma show that it is well tolerated and 31 percent of patients have achieved a response at the 2 mg/kg dose, and 67 percent in dose cohorts above 4 mg/kg achieving response. Daratumumab is a product in development by Genmab A/S, of Copenhagen, Denmark.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription